checkAd

     149  0 Kommentare Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - Seite 3

    CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

    Contact:
    Cytokinetics
    Diane Weiser
    Senior Vice President, Corporate Affairs
    (415) 290-7757



    globenewswire
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - Seite 3 Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety …

    Schreibe Deinen Kommentar

    Disclaimer